[Imipenem-cilastatin in the treatment of suppurative inflammatory complications in the cancer clinic].
The results of the treatment with imipenem/cylastatin (Merck, Sharp and Dohme) of 46 oncological patients whose condition was severe or extremely severe because of infectious complications are presented. The drug was administered intravenously drop-like in doses of 1.5 or 2 g a day. The paper also presents the data on the in vitro susceptibility of 492 strains of aerobic organisms causing purulent inflammatory and septic complications. The majority of the strains were susceptible to imipenem/cylastatin (80-100 per cent depending on the genus and species). A complete or partial therapeutic effect was observed in 30 out of 46 patients. The adverse reactions in several cases required the use of some other drug. Still, they were not life-threatening. Therefore, imipenem/cylastatin should be considered to be a highly efficient combination with antibacterial action. It is useful in the treatment of severe purulent inflammatory complications in oncological patients.